Skip to content

Author

S. K. Klein

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM.

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly, systemic symptoms, and anemia, the latter being strongly associated with poor survival and reduced quality of life. Current Janus kinase (JAK) inhibitors improve symptoms and spleen size but often exacerbate anemia, leaving a sig...

S. A. L. Wever, M. Hoogendoorn, S. K. Klein et al. · 0 citations
Open access Sep 2026

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing, and Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.

Zaid N. Al Shirity, P. Mian, A. Dontje et al. · 0 citations
Open access Sep 2026

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics.

Assessing the coexistence of normal and pathologic MCs is a widely available, fast, and sensitive diagnostic and prognostic tool and may also be used in SM disease follow-up and treatment monitoring.

Abdulrazzaq Alheraky, K. Meijer, Marije T. Nijk et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.